Enzo Biochem to produce single-copy DNA for treatment of genetic diseases, cancer

By Lisa Kerner

Erie, Pa., May 23 - Enzo Biochem, Inc. said it will enter into the cytogenetics market by producing newly patented single-copy DNA probes for use in the treatment of genetic diseases and cancers.

The probes drill down to the DNA level to see that the cause of disease may be slightly different between patients with the same diagnosis, according to a company news release.

The company acquired a license to the technology from the Children's Mercy Hospital & Clinics in Kansas City, Mo., as well as rights to any patents relating to the technology issued in the future. Enzo also acquired rights to approximately 50 DNA probes able to identify a number of genetic maladies.

Enzo said it plans to combine the probes with its proprietary signal amplification technologies.

"This is an exciting and important new product for Enzo, and it marks the first time our company has acquired an inline license for a technology that fits so well with the expertise we have developed over the years in gene identification," chief executive officer and chairman Elazar Rabbani said in the release.

Located in Farmingdale, N.Y., Enzo Biochem is engaged in the research, development and manufacture of health care products based on molecular biology and genetic engineering techniques.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.